Equity Overview
Price & Market Data
Price: $2.81
Daily Change: +$0.035 / 1.25%
Range: $2.78 - $2.82
Market Cap: $34,799,612
Volume: 1,306
Performance Metrics
1 Week: -5.52%
1 Month: 9.60%
3 Months: -11.51%
6 Months: -33.91%
1 Year: 86.39%
YTD: -40.43%
Company Details
Employees: 31
Sector: Health technology
Industry: Pharmaceuticals: major
Country: Switzerland
Details
Relief Therapeutics Holding SA, a biopharmaceutical company, engages in identification, development, and commercialization of novel, patent protected products for the treatment of dermatological, metabolic, and pulmonary rare diseases in Switzerland, Europe, North America, and internationally. The company offers SETOFILM/ONDISSOLVE for nausea and vomiting associated with radiotherapy-induced, chemotherapy, and postoperative sequels; ACER-001, a sodium phenylbutyrate for the treatment of urea cycle disorders; and PKU GOLIKE for the dietary management of phenylketonuria. It also develops RLF-100, a synthetic form of vasoactive intestinal peptide for the treatment of acute respiratory distress syndrome and certain chronic lung diseases, including sarcoidosis, berylliosis, and checkpoint inhibitor-induced pneumonitis. In addition, the company develops RLF-TD011, a hypochlorous acid solution for epidermolysis bullosa. Further, it is developing RLF-OD32, a next-generation liquid sapropterin formulation for phenylketonuria. Relief Therapeutics Holding SA was founded in 2013 and is based in Geneva, Switzerland.